Get the Stockscreener App
0.9008
8.08%
-0.0792
After Hours:
.90
-0.0008
-0.09%
Acumen Pharmaceuticals Inc stock is traded at $0.9008, with a volume of 487.25K.
It is down -8.08% in the last 24 hours and down -29.62% over the past month.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
See More
Previous Close:
$0.98
Open:
$0.98
24h Volume:
487.25K
Relative Volume:
1.94
Market Cap:
$66.63M
Revenue:
-
Net Income/Loss:
$-64.86M
P/E Ratio:
-0.8043
EPS:
-1.12
Net Cash Flow:
$-55.66M
1W Performance:
-11.69%
1M Performance:
-29.62%
6M Performance:
-66.14%
1Y Performance:
-74.04%
1-Day Range:
$0.8686
$1.02
1-Week Range:
$0.8686
$1.15
52-Week Range:
$0.8686
$3.92
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Name
Acumen Pharmaceuticals Inc
Sector
Industry
Phone
925-368-8508
Address
427 PARK ST., CHARLOTTESVILLE
Compare ABOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
0.9008 | 66.63M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-26-24 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-20-23 | Resumed | BofA Securities | Buy |
| May-18-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-15-22 | Initiated | BTIG Research | Buy |
| Jun-30-22 | Initiated | H.C. Wainwright | Buy |
| Jan-21-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-26-21 | Initiated | BofA Securities | Neutral |
| Jul-26-21 | Initiated | Credit Suisse | Outperform |
| Jul-26-21 | Initiated | Stifel | Buy |
| Jul-26-21 | Initiated | UBS | Buy |
View All
Acumen Pharmaceuticals Inc Stock (ABOS) Latest News
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting - The Manila Times
Game-Changing Trial Screening Method: Acumen Advances Alzheimer's Research with pTau217 Innovation - Stock Titan
Charles Schwab Investment Management Inc. Acquires 18,004 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors - The Manila Times
What is HC Wainwright’s Forecast for ABOS FY2029 Earnings? - Defense World
FY2029 Earnings Forecast for ABOS Issued By HC Wainwright - The AM Reporter
UBS Group Lowers Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target to $4.00 - Defense World
Acumen Pharmaceuticals outlines ALTITUDE AD Phase 2 plans and late 2026 data timeline - MSN
HC Wainwright Has Lowered Expectations for Acumen Pharmaceuticals (NASDAQ:ABOS) Stock Price - Defense World
Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Cut to $11.00 by Analysts at HC Wainwright - The AM Reporter
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2024 Earnings Call Transcript - Insider Monkey
Acumen Pharmaceuticals’ Earnings Call: Progress Amid Challenges - TipRanks
Bank of America Securities Sticks to Its Buy Rating for Acumen Pharmaceuticals (ABOS) - The Globe and Mail
Tesla To $345? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
UBS Cuts Price Target on Acumen Pharmaceuticals to $4 From $6, Keeps Buy Rating - MarketScreener
Acumen Pharmaceuticals Inc (ABOS) Q4 2024 Earnings Call Highlights: Strong Financial Position ... By GuruFocus - Investing.com Canada
Acumen Pharmaceuticals Advances Alzheimer’s Treatment Efforts - TipRanks
Earnings call transcript: Acumen Pharmaceuticals Q4 2024 focuses on Alzheimer’s innovations - Investing.com
Acumen Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights - The Manila Times
Acumen's $231M War Chest Powers Breakthrough Alzheimer's Drug Development - Stock Titan
Acumen Pharmaceuticals completes Phase 2 trial enrollment By Investing.com - Investing.com South Africa
Preview: Acumen Pharmaceuticals's Earnings - Benzinga
Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease - The Manila Times
Acumen Pharmaceuticals completes Phase 2 trial enrollment - Investing.com
Acumen Pharmaceuticals Completes Enrollment Of Altitude-Ad, A Phase 2 Clinical Trial Of Sabirnetug (Acu193) In Early Alzheimer'S Disease - Marketscreener.com
Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease - TradingView
Breakthrough Alzheimer's Treatment Advances: Phase 2 Trial Fills Ahead of Schedule - Stock Titan
Acumen Pharmaceuticals Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025 - The Manila Times
Acumen Pharmaceuticals To Report Fourth Quarter And Year-End 2024 Financial Results On March 27, 2025 - MarketScreener
Acumen Pharmaceuticals to Reveal Full Year Performance: Key Updates on Alzheimer's Treatment Progress - StockTitan
Acumen reports positive results for Alzheimer’s drug sabirnetug By Investing.com - Investing.com South Africa
Central Nervous System (CNS) Biomarkers Market Report Analysis - openPR
Acumen Pharma Reports Positive Topline Data For Sabirnetug From Phase 1 Study - Nasdaq
Acumen reports positive results for Alzheimer’s drug sabirnetug - Investing.com
Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers - The Manila Times
Breakthrough in Alzheimer's Treatment: Acumen's New Injectable Drug Shows Promise in Phase 1 - StockTitan
Chlorinated Isopropane Market Set for 4.9% CAGR Growth, Hitting USD 496.0 Million by 2035 | Fact.MR Report - GlobeNewswire
Chlorinated Isopropane Market Set for 4.9% CAGR Growth, Hitting USD 496.0 Million by 2035 | Fact.MR Report - GlobeNewswire Inc.
Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer’s - Yahoo Finance
Acumen Pharmaceuticals at UBS Virtual CNS Day: Alzheimer’s Treatment Focus - Investing.com UK
Acumen Pharmaceuticals (ABOS) Projected to Post Earnings on Tuesday - Defense World
Acumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual Meeting - The Manila Times
Acumen Pharmaceuticals, Inc. to Present Research on Sabirnetug for Alzheimer's Disease at International Conferences in April 2025 - Nasdaq
Groundbreaking Alzheimer's Drug Development: Acumen Reveals Latest Research at Two Leading Conferences - StockTitan
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Shares Sold by Rhumbline Advisers - Defense World
Alzheimer's Drug Developer Acumen Sets March Investor Presentations - StockTitan
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Cancer Immunotherapy Market Detailed In New Research Report 2025 | Gilead Sciences, Inc., Johnson & Johnson - openPR
Reviewing Acumen Pharmaceuticals (NASDAQ:ABOS) & Eloxx Pharmaceuticals (NASDAQ:ELOX) - Armenian Reporter
Acumen Pharmaceuticals Inc Stock (ABOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acumen Pharmaceuticals Inc Stock (ABOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zuga Matt | CFO & Chief Business Officer |
Jan 21 '25 |
Sale |
1.60 |
4,364 |
6,986 |
260,646 |
| OConnell Daniel Joseph | Chief Executive Officer |
Jan 21 '25 |
Sale |
1.59 |
12,619 |
20,102 |
667,488 |
| Meisner Derek M | Chief Legal Officer & Corp Sec |
Jan 21 '25 |
Sale |
1.59 |
3,418 |
5,435 |
161,127 |
| Barton Russell | Chief Operating Officer |
Jan 21 '25 |
Sale |
1.61 |
2,914 |
4,692 |
136,117 |
| Siemers Eric | Chief Medical Officer |
Jan 21 '25 |
Sale |
1.59 |
3,219 |
5,118 |
170,298 |
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):